Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Non-Current Deffered Revenue (2023 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Non-Current Deffered Revenue for 3 consecutive years, with $24.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Deffered Revenue changed 0.0% year-over-year to $24.6 million, compared with a TTM value of $24.6 million through Sep 2025, changed 0.0%, and an annual FY2024 reading of $24.6 million, up 1227950.0% over the prior year.
  • Non-Current Deffered Revenue was $24.6 million for Q3 2025 at Fennec Pharmaceuticals, roughly flat from $24.6 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $25.0 million in Q1 2024 and bottomed at $2000.0 in Q4 2023.
  • Average Non-Current Deffered Revenue over 3 years is $21.6 million, with a median of $24.6 million recorded in 2024.
  • The sharpest move saw Non-Current Deffered Revenue soared 1227950.0% in 2024, then dropped 1.73% in 2025.
  • Year by year, Non-Current Deffered Revenue stood at $2000.0 in 2023, then skyrocketed by 1227950.0% to $24.6 million in 2024, then changed by 0.0% to $24.6 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for FENC at $24.6 million in Q3 2025, $24.6 million in Q2 2025, and $24.6 million in Q1 2025.